STOMACH

Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans

A Foxx-Orenstein, M Camilleri, D Stephens, D Burton

Background: Pharmacological approaches to alter satiation may have an impact on functional upper gastrointestinal disorders and potentially change food intake in obesity.

Aim: Our aim was to compare the effects of two doses of octreotide and placebo on postprandial symptoms, gastric accommodation, and gastric emptying using validated non-invasive techniques.

Methods: In a randomised, parallel group, two dose, double blind, placebo controlled study, 39 healthy participants (13 per group) were randomised to 30 or 100 μg octreotide or placebo, administered subcutaneously, 30 minutes before each study. Studies were performed on three separate days and included scintigraphic gastric emptying of solids and liquids, 99mTc SPECT imaging to measure fasting stomach volume and gastric accommodation following a 300 ml Ensure meal, and a standardised nutrient drink test to measure maximum tolerated volume and postprandial symptoms.

Results: Relative to placebo, both doses of octreotide delayed gastric emptying of solids (not liquids), increased fasting gastric volume, reduced the change in gastric volume post meal, and decreased the sensation of fullness after a satiating meal.

Conclusion: The somatostatin analogue octreotide significantly alters human gastric functions, including inhibition of the normal reflex responses of gastric volume increase and emptying of the meal. These pharmacological effects suggest studies of the medication in disorders of satiation, including obesity and dyspepsia, are warranted.

Pharmacological approaches to alter satiation may have an impact on functional upper gastrointestinal disorders and potentially change food intake in obesity. One of the modulators of upper gastrointestinal function is the neurotransmitter somatostatin. Somatostatin exerts physiological actions via a family of six G protein coupled receptors (sst1, sst2A, sst2B, sst3, sst4, sst5). The cyclised analogue octapeptide, octreotide, binds preferentially to type 2 receptors. Several studies have addressed the effects of somatostatin or the synthetic analogue octreotide on human gastrointestinal motor functions in health and disease states. The native hormone, somatostatin, induces migrating motor complexes in the small intestine, and this is synchronised with secretary and motor activities of the gall bladder and pancreas. At a dose of 50 μg subcutaneously, octreotide induces inhibition of antral motor function, and induces phase III-like complexes in the small bowel in all patients with functional or organic motility disorders of the upper gut as well as in healthy controls. Following the activity front, there is a prolonged period of quiescence or a second, usually normally propagated activity, front in 30% of subjects. This may contribute to the delay in small bowel transit previously reported. In fact, the effects of octreotide on transit through the human gastrointestinal tract are most prominent in the small intestine. Radiolabelled solid residue traverses the small bowel at rates that are twice as slow with octreotide (50 μg three times daily) compared with placebo treatment in healthy individuals. Thus the somatostatin analogue affects predominantly small bowel transit and to date its therapeutic application has reflected this function (for example, in the short bowel syndrome, diabetic diarrhoea, or dumping syndrome). Octreotide is effective in slowing gastric and oroaeceleal transit in irritable bowel syndrome and this is accompanied by inhibition of several gastrointestinal hormones that are involved in mediating some of the fluid fluxes and motor responses to meal ingestion.

The inhibitory effects of somatostatin on smooth muscle function in the vasculature has led to important advances in the treatment of portal hypertension. Octreotide inhibited colonic tone in the postprandial period, and reduced colonic sensation in healthy volunteers and in patients with irritable bowel syndrome. Intestinal mechanosensitive afferents are modulated by somatostatin. The effect of octreotide on human gastric sensation and accommodation is unclear. In two small studies using invasive techniques (barostat balloon), inconsistent effects on gastric tone, compliance, and sensation were noted with somatostatin infusion and octreotide.

Our aim was to use non-invasive validated techniques to compare the effects of two doses of the somatostatin analogue octreotide and placebo on postprandial symptoms, gastric accommodation, and gastric emptying in healthy human volunteers.

MATERIALS AND METHODS

Experimental design and participants

This randomised, parallel group, two dose (30 and 100 μg), double blind, placebo controlled, single centre study was conducted in 39 healthy volunteers between the ages of 18 and 65 years recruited from the local community through public advertisement. Thirteen participants were randomly allocated to each treatment group in the parallel design study. Exclusion criteria included abdominal surgery other than appendectomy, positive symptoms on an abridged bowel disease questionnaire, use of medications that may

Abbreviations: SPECT, single photon emission computed tomography; VAS, visual analogue scale; IQR, interquartile range
alter gastrointestinal activity or interact with study medications, history of gall stone or biliary tract disease, known intolerance or allergy to eggs, any gastrointestinal illness or systemic condition that could affect gastrointestinal activity, or any over the counter medications taken within seven days of the study. The study was approved by Mayo Foundation’s Institutional Review Board. Eligible subjects gave their written consent and were randomised to receive either octreotide (Sandostatin; Novartis, East Hanover, New Jersey, USA) 30 μg or 100 μg, or saline (placebo).

Study medications
Following the initial screening, subjects were randomised to receive 30 μg octreotide, 100 μg octreotide, or placebo. Compared with the native hormone somatostatin, the cyclised peptide analogue octreotide is highly resistant to enzymatic degradation and has a prolonged plasma half life of approximately 100 minutes in humans. The volume of distribution of octreotide ranges from 18 to 30 litres. Mean peak plasma concentrations are between 2 and 4 μg/l in patients receiving 50–100 μg.

The study medications were prepared and dispensed by the Research Pharmacy of the Mayo General Clinical Research Center in a randomised order; all of the study medications were identical in appearance. The clinical investigators, study personnel, and volunteers were blinded to the treatment assignments until after the data analysis was complete.

Study procedures
The study was performed on three non-consecutive days with one test performed on each study day; the order of the tests was not standardised to avoid an order effect. Subjects presented to the study centre in the fasting state on each day. Randomly assigned blindly allocated doses of octreotide or placebo were administered subcutaneously by a study nurse 30 minutes before the start of each test. A standard scintigraphic gastric emptying test was performed on one day. A 99mTc sulphur colloid labelled egg meal was used to assess gastric emptying. The eggs were served with one slice of buttered bread and an eight ounce glass of 1% milk (total calories: 296 kcal, 32% protein, 35% fat, 33% carbohydrate). Anterior and posterior gamma camera images were obtained with the SPECT camera, allowing visualisation of three dimensional images of the stomach. The images are 16 minutes in duration, and three were obtained: one during fasting (after administration of the subcutaneous injection), and two sequentially after the standard 300 ml Ensure meal. The 99mTc SPECT technique involves infusion of 99mTc that is taken up by the gastric mucosa. Dynamic tomographic images are obtained with the SPECT camera, allowing visualisation of three dimensional images of the stomach. The images are 16 minutes in duration, and three were obtained: one during fasting (after administration of the subcutaneous injection), and two sequentially after the standard 300 ml Ensure meal. The 99mTc SPECT technique accurately and reliably demonstrates changes in gastric volume. Briefly, tomographic images of the gastric wall are obtained throughout the long axis of the stomach using a dual head gamma camera (SMV SPECT System; SMV America, Twinsburg, Ohio, USA) that rotates around the body. This allows assessment of the radiolabelled circumference of the gastric wall rather than the intragastric content. Using the AWV 3.0 (Biomedical Imaging Resource, Mayo Foundation, Rochester, Minnesota, USA) image processing libraries, a three dimensional rendering of the stomach is obtained and its volume (ml) calculated. Radiation exposures from the scintigraphic gastric emptying and SPECT gastric accommodation tests were previously published in detail. Radiation effective doses (H2) are 90 mrem for gastric emptying and 619 mrem for gastric accommodation tests.

On a separate day, participants underwent the “satiety test” to assess postprandial symptoms and gastric emptying of nutrient liquids. An adaptation of the method of Tack et al was used to measure the maximum tolerated volume. Subjects ingested 30 ml of a nutrient drink (Ensure 1 kcal/ml) at 15 minutes during the second hour, and at 30 minute intervals for the third hour. Thirty minutes after reaching the maximum tolerated volume, participants scored their symptoms of bloating, fullness, nausea, and pain using 100 mm visual analogue scales (VAS) anchored with the words “unnoticeable” and “unbearable” at the left and right ends (that is, maximum score 100 for each symptom). The aggregate symptom score was defined as the sum of the VAS scores for each symptom (that is, maximum score 400). We have reported normal values for the nutrient drink test in adolescents and adults.

Gastric accommodation is a robust vagally mediated reflex in health which results in reduced gastric tone, increased compliance, and increased gastric volume. Accommodation allows ingestion of large volumes of solids or liquids without inducing postprandial symptoms. An abnormally low postprandial gastric volume may contribute to the development of symptoms in patients with functional dyspepsia, post vagotomy surgery, post fundoplication dyspepsia, rumination syndrome, and diabetic vagal neuropathy. A non-invasive method has been developed and validated in our laboratory to measure fasting and postprandial gastric volumes using an intravenous injection of 99mTc pertechnetate (99mTcO4−) and imaging with SPECT. Tomographic images were acquired on a large field of view dual headed gamma camera system (SMV SPECT System; SMV America). Gastric volumes were measured using the SPECT-ANALYZE PC 2.5 (Biomedical Imaging Resource) software system. There is a high degree of correlation between volumes measured by SPECT and barostat balloon in response to distension and to a meal.

The gastric mucosa can take up intravenously administered 99mTc pertechnetate (99mTcO4−) from the circulating blood pool. Starting 10 minutes after intravenous injection of 10 mCi 99mTcO4− imaging was performed during fasting and for a total of 32 minutes after injection of a 300 ml nutrient drink (Ensure 1 kcal/ml) through a straw. Gastric volumes were assessed during two postprandial periods: 0–10 minutes and 10–20 minutes following the meal. Transaxial images of the stomach were rendered with ANALYZE to reconstruct three dimensional images and to measure gastric volumes during the fasting and postprandial
periods. Volume changes and ratios between the fasting and postprandial periods were calculated.

Data analysis
The geometric mean of counts in the anterior and posterior gastric regions of interest was used to estimate the gastric emptying T½ of solids and liquids. A second important transit end point was lag time, or time taken for emptying of 10% of the solid meal.

The maximum tolerated volume of nutrient drink ingested was recorded. Individual symptoms scores (maximum score 100) for bloating, fullness, nausea, and pain and the aggregate symptom score, the sum of the individual symptom scores (maximum score 400), were documented.

Fasting and postprandial gastric volumes were measured by ANALYZE using reconstructed three dimensional images of the stomach. Two time periods, 0–16 and 17–32 minutes following the meal, were assessed and the average of these two postprandial gastric volume estimates calculated. While it is possible to separate the stomach volume into a proximal and distal segment using this technique (for example, based on the location of the incisura), anatomical variations between individuals (for example, the shape of the stomach, clarity of the incisura, axis of the stomach) make any division arbitrary and potentially erratic as a means to compare the effects of octreotide on different gastric regions. Hence our choice to evaluate effects on the entire stomach rather than subregions of the stomach.

Statistical methods
The primary end points selected for analysis were maximal volume of Ensure tolerated; the aggregate symptom score 30 minutes after ingestion of Ensure; T½ of gastric emptying of solid and nutrient liquid; and fasting gastric volume and change in gastric volume following the standardised meal. Secondary end points were individual postprandial symptoms scores.

The effects of the three treatments on transit parameters, gastric volumes, and symptom scores were compared using analysis of variance on ranks (Kruskal-Wallis test). Two specific (a priori) contrasts (at α = 0.05) among treatment groups based on the ANOVA on ranks were examined (overall drug v placebo and each dose (30, 100 μg) of octreotide v placebo) using an appropriate multiple comparison procedure (Dunn’s method). All analyses were performed using SigmaStat (version 2.0 for Windows 95, NT & 3.1, 1997; SPSS Inc., Chicago, Illinois, USA).

Sample size assessment
With 13 subjects per group, we anticipated the analysis of variance would provide 80% power to detect pairwise

<table>
<thead>
<tr>
<th>Table 1 Participant demographics in the three groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo group</td>
</tr>
<tr>
<td>Age (y)</td>
</tr>
<tr>
<td>Sex (M/F)</td>
</tr>
<tr>
<td>Height (m)</td>
</tr>
<tr>
<td>Weight (kg)</td>
</tr>
<tr>
<td>Body mass index</td>
</tr>
</tbody>
</table>

Values are mean (SD).

Figure 1  Effect of octreotide 30 and 100 μg compared with placebo on gastric half emptying time for solids. (A) Median, interquartile range, and full range. (B) Scatterplot of all data. Note that both doses of octreotide retarded gastric emptying.

Figure 2  Effect of octreotide 30 and 100 μg compared with placebo on gastric emptying lag time (time at 10% emptied) for solids. (A) Median, interquartile range, and full range. (B) Scatterplot of all data. Note that only octreotide 100 μg prolonged gastric emptying lag time.
differences using a pooled estimate of variation across all three groups, based on previously published data for satiety testing and gastric accommodation in healthy volunteers and in patients with non-ulcer dyspepsia, and scintigraphic transit studies.

RESULTS

Participant characteristics
Forty volunteers were screened and 39 were enrolled into the study. One volunteer who was screened developed influenza symptoms and was withdrawn from the study before randomisation. All 39 volunteers completed the study. Volunteer demographics are shown in table 1. No significant differences in age, sex, height, weight, or body mass index were detected between the groups.

Effect of octreotide on gastric emptying of solids and liquids
Octreotide delayed gastric emptying $T_{1/2}$ (p<0.001) and lag time ($p = 0.016$) relative to placebo (figs 1, 2); this retardation of $T_{1/2}$ was significant for both doses of octreotide tested ($p<0.05$ with correction for multiple comparisons) but only the 100 µg dose prolonged the lag time for emptying of solids.

The effect of octreotide on liquid emptying $T_{1/2}$ was not significant (placebo: median 180 minutes (interquartile range (IQR) 133–180); octreotide 30 µg: 163 minutes (IQR 85–180); octreotide 100 µg: 80 minutes (IQR 42–180)).

Effect of octreotide on gastric volumes
Octreotide increased fasting gastric volume (fig 3) relative to placebo ($p = 0.024$); this effect was significant for both the 30 and 100 µg doses ($p<0.05$ with correction for multiple comparisons). In contrast, the postprandial total gastric volume was greater with placebo (median volume 817 ml (IQR 775–870)) than with 30 µg (median volume 693 ml (IQR 617–745)) or 100 µg octreotide (median volume 695 ml (IQR 602–733)). Similarly, the change in postprandial volume (fig 4) relative to fasting was significantly lower with octreotide relative to placebo ($p<0.001$), and this effect was also significant for both doses tested (both $p<0.05$ with correction for multiple comparisons).

Postprandial volumes in the placebo treated group were not different between the first (0–16 minutes) and second (17–32 minutes) measurements in the postprandial period. In contrast, volumes were significantly lower during the second periods with both doses of octreotide (fig 5).

Figure 3. Effect of octreotide on gastric volumes measured by single photon emission computed tomography imaging after 99mTc pertechnetate injection. (A) Reconstructed images of the stomach during fasting and postprandially after placebo and octreotide 30 and 100 µg treatment. (B) Median, interquartile range, and full range of fasting gastric volumes. (C) Scatterplot of all data. Note that both doses of octreotide retarded the increase in fasting gastric volumes.
higher in the first than in the second period when volunteers received octreotide.

Figure 4  Effect of octreotide 30 and 100 µg compared with placebo on change in gastric volume with ingestion of a standard 300 ml Ensure meal. Note that both doses of octreotide reduced the postprandial increase in gastric volume.

Maximum tolerated volume and postprandial symptoms
Octreotide did not significantly alter the maximum volume ingested at the point of maximum satiation (placebo: median volume 1331 ml (IQR 1184–1540); octreotide 30 µg: 1335 ml (IQR 1084–1540); and octreotide 100 µg: 1384 ml (IQR 1221–1895)), or the aggregate postprandial symptom score 30 minutes later (table 2). Of the individual symptoms which were analysed for descriptive purposes as secondary end points (table 2), only fullness was significantly reduced by octreotide (p = 0.029; fig 6), and this effect was significant only for the 100 µg dose (p<0.05 with correction for multiple comparisons).

DISCUSSION
This study has demonstrated the effects of octreotide on fasting and postprandial gastric volumes. Our study confirms retardation of gastric emptying of solids by octreotide, previously demonstrated in some reports. In addition, we have provided data on the effects on gastric emptying of two doses of octreotide that are commonly used to treat dumping syndrome in clinical practice. The effects of octreotide on postprandial sensation can be evaluated more thoroughly, in view of the observations on gastric emptying and volumes in the same participants.

Octreotide increases fasting gastric volume and this is consistent with the inhibitory effects of the somatostatin analogue on gastrointestinal contractility or tone in the stomach and elsewhere in the digestive tract. In a study of 13 male volunteers, Mertz and colleagues9 showed that higher doses (1.25 µg/kg subcutaneously) of octreotide increased stomach volume responses to phasic distensions of an intragastric balloon (suggesting increased compliance) and the reduced sensation of fullness during volume based gastric distensions. However, the effects of octreotide on sensation were not replicated during ramp inflation by these9 or other authors.26 Our study showed that, under physiological conditions and in the absence of invasive intubation, octreotide increased fasting gastric volume, an effect which may reflect the ability of somatostatin to regulate neurotransmitter release,19 activate nitrergic mechanisms,18 or reduce enteric neuronal excitability by postjunctional effects.28 32

By way of contrast, the volume of the stomach after a standard 300 ml Ensure meal was not larger with octreotide than with placebo treatment. In fact, the change in volume to the same Ensure volume and calorie load was, on average, 200 ml smaller with each of the two octreotide doses than placebo. This might be considered paradoxical given the observed increase in fasting gastric volume. However, gastric emptying measurements based on planar (two dimensional) imaging do not accurately reflect actual intragastric volume; these measurements merely track the rate of emptying of the radioisotopic marker tagging the meal substrate. In contrast, the SPECT method provides an assessment of the radio-labelled circumference of the gastric wall (from which the
visual analogue scale. octreotide 100 g reduced fullness relative to placebo treatment. VAS, visual analogue scale.

Table 2 Postprandial symptoms 30 minutes after a maximally tolerated volume of Ensure

<table>
<thead>
<tr>
<th>Symptom scores</th>
<th>Placebo group</th>
<th>Octreotide 30 µg group</th>
<th>Octreotide 100 µg group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aggregate</td>
<td>178 (152–219)</td>
<td>179 (179–227)</td>
<td>127 (75–250)</td>
</tr>
<tr>
<td>Fullness*</td>
<td>84 (71–91)</td>
<td>70 (60–83)</td>
<td>65 (33–78)**</td>
</tr>
<tr>
<td>Nausea†</td>
<td>40 (15–58)</td>
<td>14 (0–30)</td>
<td>14 (5–56)</td>
</tr>
<tr>
<td>Bloating†</td>
<td>57 (45–74)</td>
<td>68 (49–81)</td>
<td>40 (26–64)</td>
</tr>
<tr>
<td>Pain</td>
<td>11 (2–26)</td>
<td>14 (1–35)</td>
<td>4 (1–46)</td>
</tr>
</tbody>
</table>

Data are median scores (interquartile range). Maximum aggregate score = 400; maximum individual score = 100.

* p = 0.029, ** p<0.05 versus placebo (ANOVA on ranks with Dunn’s test).

The greater fasting volume with octreotide than placebo suggests that the effect of the somatostatin analogue results either by a direct effect (for example, by its postjunctional effects on enteric neuronal excitability) or through an inhibitory pathway (for example, by activating nitrergic neurones). The normal increase in stomach volume in response to a meal represents a distension and nutrient mediated reflex. The reflex involves the release of peptides and other transmitters such as serotonin and cholecystokinin from the upper gastrointestinal mucosa, activation of vagal afferents, and stimulation of vagal efferents that activate intrinsic inhibitory nerves to induce gastric relaxation and enhance gastric volume.

The current studies do not permit a definitive characterisation of the site of action of octreotide. Somatostatin and octreotide inhibit release of many gastroenteropancreatic hormones in response to meal ingestion. The effects of octreotide may be, at least partly, mediated through effects on afferent nerves. Thus experimental evidence using single fibre recordings from mesenteric and vagal afferents have shown that octreotide reduces afferent firing in response to distension. This may result in the reduced volume response and reduced activation of antral contractility that normally leads to trituration and emptying of solid food.

Wall tension or afferent nerve function may both contribute to the level of sensation; also suggested that the effects of octreotide on gastric sensation were partly attributable to the motor effects of octreotide on gastric compliance. We cannot exclude this effect given the significant effects on volume based distensions. In our study, maximum tolerated volumes of Ensure were not smaller, and postprandial symptoms were not higher relative to placebo treatment despite lower postprandial volume. These data suggest that postprandial sensation was not determined solely by postprandial gastric volume, and the data are more consistent with the effects of octreotide on afferent function, as previously shown in the rumen.

Another intriguing observation is that postprandial volumes were not different during the two postprandial measurements under placebo treatment. In contrast, with both octreotide doses, there were consistently lower gastric volumes during the second postprandial measurement. The latter observation may suggest that effects of octreotide on the mechanisms that result in increased gastric volume might change over time in the postprandial period. We do not believe this is due to the pharmacokinetic properties of octreotide as the motor actions of the drug are virtually immediate after subcutaneous injection, and the pharmacodynamic actions are demonstrable for at least 2–4 hours after administration, as shown by the effects on gastric emptying of solids. Moreover, the inhibitory effect of octreotide on postprandial volume is greater in the second measurement relative to the first period. This would be opposite to what would be expected if the effects of the drug reflected only the lower circulating levels of octreotide in the second period. Another possible explanation is that there is a greater effect of octreotide on nutrient mediated activation of the accommodation reflex compared with inhibition of the volume increase in response to the mechanical distension of the stomach by the meal. This hypothesis requires further study.

Figure 6 Effect of octreotide 30 and 100 µg compared with placebo on fullness scores 30 minutes after ingestion of a fully satiating meal of Ensure meal. A scatterplot of all of the data is shown. Note that octreotide 100 µg reduced fullness relative to placebo treatment. VAS, visual analogue scale.
gastrointestinal disorders associated with early satiation and weight loss. 

In summary, octreotide has important effects on stomach emptying, sensation, and volumes; this study in healthy individuals has provided novel insights that require further testing in disease states.

ACKNOWLEDGEMENTS

This study was supported in part by grants R01 DK-54681 (MC) and K24 DK-12638 (MC) from the National Institutes of Health. We thank Mrs Cindy Stanislav for excellent secretarial assistance.

Authors’ affiliations
A Foxx-Orenstein, M Camilleri, D Stephens, D Burton, Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER) Program, Mayo Clinic, Rochester, MN, USA

REFERENCES